Amgen Inc.'s rise in second-quarter earnings and the overseas deal with GlaxoSmithKline plc for denosumab sent the stock up last week, but left questions about the rest of 2009 as well as the bone-drug pipeline star, especially with regard to osteonecrosis of the jaw - a side effect that has also bedeviled (apparently to a lesser extent) competitor Zometa. Read More
